ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1910

Validation Of The Mayo Hip Questionnaire: Validity and Sensitivity To Change

Jasvinder A. Singh1, Cathy Schleck2, W. Scott Harmsen3 and David Lewallen4, 1Department of Medicine, University of Alabama, Tuscaloosa, AL, 2Mayo Clinic College of Medicine, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Orthopedics, Mayo Clinic college of medicine, Rochester, MN

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Hip, Joint replacement, outcome measures and patient outcomes, Validity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery

Session Type: Abstract Submissions (ACR)

Background/Purpose: Mayo Hip questionnaire has previously been shown to have face, content and test-retest reliability. Our objective was to assess the validity and responsiveness of the Mayo Hip Questionnaire.

Methods: We used data from the Mayo Clinic Total Joint Registry to assess the validity of Mayo Hip questionnaire, by including patients who underwent primary total hip arthroplasty (THA) between 1993-2005 and responded to the baseline and 2-year post-primary THA Mayo Hip questionnaire.  Mayo hip questionnaire assesses the domains of pain, function and mobility; reliability and construct validity has been previously established. It generates a total score clinical score ranging 0-80 (Excellent result is 72-80 points, good is 64-71 points, fair is 56-63 points, and poor is less than 55 points). Convergent/divergent validity was examined with the association of select demographics (age, gender, number of joints involved) at baseline with Mayo hip scores using linear regression analyses.  Minimally Clinically Important Difference (MCID) and Really Important Difference (RID) were calculated corresponding to “somewhat better now” and “much better now”, respectively in response to patient-reported anchor at 2-years- Compared to your condition before the surgery, how would you rate your hip now?  For discriminant ability, we calculated a) effect size by taking the change in respective score from baseline to 2-years and dividing the result by the standard deviation at baseline and b) the standardized response mean, defined as the mean change in the patient score with improvement at 2-years divided by the SD of the changed scores.

Results: For primary THA, there are 2,311 hips with both a baseline and a 2-year data. The sample consisted of 1,097 males (47.5%)and 1,214 females (52.5%). The mean age at surgery (SD) is 64 (13), median was 66 (range, 15-92).  Age and gender were significantly associated Mayo Hip score at 2-years post-THA (p<0.001); and the number of joints involved was not associated (p=0.98).  MCID was 24.8 and RID threshold was 37.1.  Effect size at 2-years was large, 2.26 and the Standardized Response Mean was 2.25. 

Conclusion: The Mayo Hip questionnaire is a valid and sensitive outcome measure for patients undergoing primary THA. This study provides further validation of this previously validated scale.  Further validation in revision THA and in more diverse populations will provide more support to its validation as an outcome instrument.


Disclosure:

J. A. Singh,

Takeda, Savient,

2,

Savient, Takeda, Ardea, Regeneron, Allergan,

5,

URL pharmaceuicals Novartis,

5;

C. Schleck,
None;

W. S. Harmsen,
None;

D. Lewallen,

DePuy, Stryker, Biomet and Zimmer.,

2,

Zimmer, Orthosonic and Osteotech,

7,

Pipeline,

5,

Pipeline,

1.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-mayo-hip-questionnaire-validity-and-sensitivity-to-change/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology